An alternative option, however, could be to selectively target specific hyperactive or overexpressed CaM-dependent proteins in tumor cells by blocking their respective CaM-binding sites as we have previously suggested (reviewed in [27,343]). The gene discussed is CALM1; the disease is neoplasm.